

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

PAR PHARMACEUTICAL, INC., and  
ROXANE LABORATORIES, INC.  
Petitioners

v.

JAZZ PHARMACEUTICALS, INC.  
Patent Owner

---

CASE IPR: Unassigned  
Patent 7,668,730

---

**PAR PHARMACEUTICAL, INC., AND ROXANE LABORATORIES,  
INC.'S EXHIBIT LIST (COVERED BUSINESS METHOD PATENT  
REVIEW OF U.S. PATENT NO. 7,668,730 )**

***Mail Stop "PATENT BOARD"***  
Patent Trial and Appeal Board  
U.S. Patent and Trademark Office  
P.O. Box 1450  
**Alexandria, VA 22313-1450**

***Covered Business Method Patent Review of USPN 7,668,730  
Par and Roxane Exhibit List***

<b><i>Par Exhibit #</i></b>	<b><i>Description</i></b>
<b>1001</b>	Reardan, <i>et al.</i> , U.S. Patent No. 7,668,730 (filed Dec. 17, 2002; issued Feb. 23, 2010)
<b>1002</b>	File History for U.S. Patent No. 7,668,730 (filed Dec. 17, 2002; issued Feb. 23, 2010)
<b>1003</b>	FDA Peripheral & Central Nervous System Drugs Advisory Committee, Transcript and Slides
<b>1004</b>	FDA Peripheral & Central Nervous System Drugs Advisory Committee, Briefing Information, Division of Neuropharmacological Drug Products Preliminary Clinical Safety Review of NDA 21-196
<b>1005</b>	FDA Peripheral & Central Nervous System Drugs Advisory Committee, Briefing Information, Briefing Booklet
<b>1006</b>	FDA Peripheral & Central Nervous System Drugs Advisory Committee, Briefing Information, Xyrem Video and Transcript
<b>1007</b>	Declaration of Dr. Robert J. Valcuk, Ph.D., R.Ph. (“Valuck Dec.”)
<b>1008</b>	<i>Curriculum Vitae</i> of Dr. Robert J. Valuck, Ph.D., R.Ph.
<b>1009</b>	Shulman, S., “The Broader Message of Accutane,” <i>Am. J. of Public Health</i> , 79:1565-1568 (1989)
<b>1010</b>	Spurgeon, D., “Advent of Mail-Order Pharmacy Causes Concern Among Some Pharmacists,” <i>Can. Med. Assoc. J.</i> , 152:1485-1486 (1995)
<b>1011</b>	Honigfeld, G., “Effects of the Clozapine National Registry System on Incidence of Deaths Related to Agranulocytosis,” <i>Psychiatric Services</i> , 47:52-56 (1996)
<b>1012</b>	Burleson, K., “Review of computer applications in institutional pharmacy—1975-1981,” <i>Am. J. Hosp. Pharm.</i> , 39:53-70 (1982)
<b>1013</b>	Zeldis, J., <i>et al.</i> , “S.T.E.P.S. <sup>TM</sup> : A comprehensive Program for Controlling and Monitoring Access to Thalidomide,” <i>Clin. Therapeutics</i> , 21:319-330 (1999)

***Covered Business Method Patent Review of USPN 7,668,730  
Par and Roxane Exhibit List***

<b><i>Par Exhibit #</i></b>	<b><i>Description</i></b>
<b>1014</b>	“Managing the Risks from Medical Product Use: Creating a Risk Management Framework,” Report to the FDA Commissioner from the Task Force on Risk Management, U.S. Dept. of Health and Human Services, Food and Drug Administration (1999)
<b>1015</b>	66 Fed. Reg. 24391
<b>1016</b>	INTENTIONALLY LEFT BLANK
<b>1017</b>	FDA Center for Drug Evaluation and Research, 2001 FDA Advisory Committee’s Meeting Documents by Center, <i>available at</i> <a href="http://www.fda.gov/ohrms/dockets/ac/01docsbc.htm">http://www.fda.gov/ohrms/dockets/ac/01docsbc.htm</a>
<b>1018</b>	Internet Archive Wayback Machine, Center for Drug Evaluation and Research 2001 Meeting Documents, <i>available at</i> <a href="https://web.archive.org/web/20010617210030/http://www.fda.gov/ohrms/dockets/ac/cder01.htm">https://web.archive.org/web/20010617210030/http://www.fda.gov/ohrms/dockets/ac/cder01.htm</a> (dated June 17, 2001)
<b>1019</b>	Internet Archive Wayback Machine, FDA Peripheral & Central Nervous System Drugs Advisory Committee, Briefing Information for Xyrem NDA 21-196, <i>available at</i> <a href="https://web.archive.org/web/20010701233052/http://www.fda.gov/ohrms/dockets/ac/01/briefing/3754b1.htm">https://web.archive.org/web/20010701233052/http://www.fda.gov/ohrms/dockets/ac/01/briefing/3754b1.htm</a> (dated July 1, 2001)
<b>1020</b>	Internet Archive Wayback Machine, Center for Drug Evaluation and Research 2001 Meeting Documents, <i>available at</i> <a href="https://web.archive.org/web/20011004081740/http://www.fda.gov/ohrms/dockets/ac/cder01.htm">https://web.archive.org/web/20011004081740/http://www.fda.gov/ohrms/dockets/ac/cder01.htm</a> (dated Oct. 4, 2001)
<b>1021</b>	Orange Book Entries for Xyrem®, <i>available at</i> <a href="http://www.accessdata.fda.gov/scripts/cder/ob/docs/obdetail.cfm?Appl_No=021196&amp;TABLE1=OB_Rx">http://www.accessdata.fda.gov/scripts/cder/ob/docs/obdetail.cfm?Appl_No=021196&amp;TABLE1=OB_Rx</a> ; and <a href="http://www.accessdata.fda.gov/scripts/cder/ob/docs/patexclnew.cfm?Appl_No=021196&amp;Product_No=001&amp;table1=OB_Rx">http://www.accessdata.fda.gov/scripts/cder/ob/docs/patexclnew.cfm?Appl_No=021196&amp;Product_No=001&amp;table1=OB_Rx</a>
<b>1022</b>	Rome, E., “It’s a rave new world: Rave culture and illicit drug use in the young,” <i>Cleveland Clinic J. of Med.</i> , 68:541-550 (2001)

***Covered Business Method Patent Review of USPN 7,668,730  
Par and Roxane Exhibit List***

<b><i>Par Exhibit #</i></b>	<b><i>Description</i></b>
<b>1023</b>	FDA Center for Drug Evaluation and Research, NDA 21-196, Approved Labeling, <i>available at</i> <a href="http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-196_Xyrem_prntlbl_P1.pdf">http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-196_Xyrem_prntlbl_P1.pdf</a>
<b>1024</b>	INTENTIONALLY LEFT BLANK
<b>1025</b>	Complaint, <i>Jazz Pharms., Inc. v. Roxane Labs., Inc.</i> , 2:11-cv-02523 (D.N.J. May 5, 2011)
<b>1026</b>	Complaint, <i>Jazz Pharms., Inc. v. Par Pharm., Inc.</i> , 2:13-cv-07884 (D.N.J. Dec. 27, 2013)
<b>1027</b>	FDA's Center for Drug Evaluation and Research, Advisory Committees CDER 2001 Meeting Documents, <i>available at</i> <a href="http://www.fda.gov/ohrms/dockets/ac/cder01.htm#Peripheral%20&amp;%20Central%20Nervous%201/">http://www.fda.gov/ohrms/dockets/ac/cder01.htm#Peripheral%20&amp;%20Central%20Nervous%201/</a>
<b>1028</b>	Affidavit from the Internet Archive Wayback Machine
<b>1029</b>	Mitchell, A., "A Pregnancy-Prevention Program in Women of Childbearing Age Receiving Isotretinoin," <i>The New England Journal of Medicine</i> , 333:101-106 (1995)
<b>1030</b>	Moradi <i>et al.</i> , U.S. Patent Appl. Pub. No. 2004/0019794 (filed Jul. 29, 2002; published Jan. 29, 2004)
<b>1031</b>	Lilly <i>et al.</i> , U.S. Patent Appl. Pub. No. 2003/0093295 (filed Jan. 31, 2002; published May 15, 2003)
<b>1032</b>	Scrima, L., <i>et al.</i> , "Efficacy of Gamma-Hydroxybutyrate versus Placebo in Treating Narcolepsy-Cataplexy: Double-Blind Subjective Measures," <i>Biol. Psychiatry</i> , 26:331-343 (1989).

*Covered Business Method Patent Review of USPN 7,668,730  
Par and Roxane Exhibit List*

Respectfully Submitted,



Aziz Burgy  
Registration No. 51,514  
Attorney for Petitioner

Date: July 8, 2014  
ARENT FOX LLP  
1717 K Street, NW  
Washington, DC 20036  
202.857.6000

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.